Secretory carcinoma — impact of translocation and gene fusions on salivary gland tumor

Ryoko Inaki¹, Masanobu Abe^{1,2}, Liang Zong^{3,4}, Takahiro Abe¹, Aya Shinozaki-Ushiku⁵, Tetsuo Ushiku⁵, Kazuto Hoshi¹

¹Department of Oral & Maxillofacial Surgery, University of Tokyo Hospital, Tokyo 113-8655, Japan; ²Division for Health Service Promotion, University of Tokyo, Tokyo 113-003, Japan; ³Graduate School of Medicine, University of Tokyo, Tokyo 113-8654, Japan; ⁴Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China; ⁵Department of Pathology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan

Correspondence to: Masanobu Abe. Department of Oral & Maxillofacial Surgery, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan; Division for Health Service Promotion, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-003, Japan. Email: abem-ora@h.u-tokyo.ac.jp.

Abstract

Secretory carcinoma (SC), previously described as mammary analogue secretory carcinoma (MASC), is a recently described salivary gland tumor which morphologically resembles mammary secretory carcinoma. The first description of SC/MASC, reported by Skálová *et al.* in 2010, was as a rare salivary carcinoma imitating secretory carcinoma of the breast. SC/MASC is a unique salivary gland tumor with morphological overlap with acinic cell carcinoma (AciCC), mucoepidermoid carcinoma (MEC), and adenocarcinoma not otherwise specified (ADC-NOS). SC/MASC shares similar clinicopathological features with AciCC. As a critical difference between SC/MASC and AciCC, SC/MASC characteristically has the chromosomal translocation t(12;15)(p13;q25) which leads to a fusion gene between the *ETV6* gene on chromosome 12 and the *NTRK3* gene on chromosome 15. This genetic background is an important differential diagnostic finding for excluding other salivary gland tumors and may be a critical factor determining the prognosis for patients with SC/MASC. Research in recent years has provided a large body of new data on SC/MASC and suggests the possibility that the *ETV6-NTRK3* translocation could be a therapeutic target. Here, we review the morphological and clinicopathological features of SC/MASC and discuss new directions for therapy.

Keywords: Secretory carcinoma; mammary analogue secretory carcinoma; MASC; *ETV6-NTRK3* fusion gene; salivary gland tumor

Submitted Sep 20, 2017. Accepted for publication Oct 10, 2017.

doi: 10.21147/j.issn.1000-9604.2017.05.01

View this article at: <https://doi.org/10.21147/j.issn.1000-9604.2017.05.01>

Introduction

Secretory carcinoma (SC), previously known as mammary analogue secretory carcinoma (MASC), is a new entity of malignant salivary gland tumor, which is similar to mammary SC in terms of its histologic and genetic features (1,2). Mammary SC is a rare malignancy and is reported to show slow-growing and indolent behavior. It occurs more

often in younger women than in elderly women (3). Molecularly, mammary SC is the only epithelial tumor with the t(12;15)(p13;q25) translocation in breast, leading to a fusion of the *ETV6* gene from chromosome 12 and the *NTRK3* gene from chromosome 15 (4,5). The *ETV6-NTRK3* fusion gene encodes a chimeric tyrosine kinase, and this fusion results in a constitutively active chimeric tyrosine kinase mitogenic pathway and the phosphatidylinositol-3-

kinase (PI3K)-AKT pathway (6,7). In 2010, Skálová *et al.* reviewed 16 salivary gland tumor cases that were previously classified as either acinic cell carcinoma (AciCC) or adenocarcinoma not otherwise specified (ADC-NOS) (8). The authors found that all cases but one were also positive for the *ETV6-NTRK3* translocation. They specified these cases as MASC, indicating a new salivary gland tumor entity. Since the first description of SC/MASC, more than 100 additional cases have been reported (8-20).

Clinical features

Many cases of SC/MASC had been previously classified as AciCC, mucoepidermoid carcinoma (MEC), and ADC-NOS. The most common malignancies reclassified as SC were ADC-NOS (37.8%) and AciCC (12.4%) (9,21). Retrospective studies showed that 19% of parotid gland and 79% of extraparotid gland tumors that were originally diagnosed as AciCC had been reclassified as SC/MASC (14). The site of origin for MASC/SC is the parotid gland in about two-thirds of reported cases; the other sites of origin are the intraoral minor salivary gland and the submandibular gland. Compared to AciCC, SC/MASC appears more often in non-parotid sites. Recent studies suggested that most non-parotid gland tumors diagnosed as AciCC might have a high probability of being reclassified as SC/MASC (13). SC/MASC has a higher incidence of regional lymph node involvement than AciCC (9,15). SC/MASC occurs in both children and adults (13 to 72 years), with an average age of 44.2 years (8-10), and has a slight male predilection, while AciCC predominantly affects women. Based on the previously reported cases, the overall male-to-female ratio was 1.5:1 (9).

Histologic and immunohistochemical features

Histologically, the cells of this tumor consist of the microcystic, tubular, solid, and papillary architecture, and characteristically have abundant extracellular material (1,5,17,22). These growth patterns of tumor cells overlap considerably between SC/MASC and AciCC. The cyst wall may contain a single cell lining, and the cells in these foci often show hobnailing (8,10). The cystic spaces often contain eosinophilic and periodic acid-Schiff staining-positive secretory material. Immunohistochemically, SC/MASC is characterized by strong S-100 protein, mammaglobin, vimentin, whereas AciCC has moderate or weak staining for S-100 protein and vimentin (8). Recent

immunohistochemical analyses indicated that DOG1 staining was reliable for differential diagnosis. AciCC was reported to show diffuse DOG1 staining, whereas SC/MASC was negative or focal staining. Combined DOG1 and mammaglobin immunohistochemistry is reported comparable to *ETV6*-breakapart analysis for differentiating between papillary cystic variants of AciCC and SC/MASC (23-25) (Table 1). In addition, SC/MASC is known to express GATA3, pan-cytokeratin (AE1-AE3 and CAM5.2), CK7, CK8, CK18, CK19, epithelial membrane antigen (EMA), MUC1, MUC4, STAT5a, GCDFP15, adipophilin, etc., and is reported to be negative for calponin, smooth muscle actin (SMA), CK14, CK5/6, p63, etc. (8,26,27). Even with those immunohistochemical markers, some cases represent diagnostic difficulties. Zymogen-poor AciCC is difficult to be distinguished from SC/MASC without *ETV6*-breakapart analysis.

Gene translocations and gene fusions

Translocations are speculated to occur in about 20% of all cancers. In the salivary gland, four cancers have been reported harboring recurrent translocations (28,29). These include adenoid cystic carcinoma (AdCC), hyalinizing clear cell carcinoma (HCCC), MEC, and the newly identified SC (11,28) (Table 2).

SC/MASC harbors a t(12;15)(p13;q25) translocation that results in an *ETV6-NTRK3* fusion product (19). The *ETV6-NTRK3* fusion gene encodes a chimeric tyrosine kinase, and this fusion results in a constitutively active chimeric tyrosine kinase mitogenic pathway and the PI3K-AKT pathway (6,7). This fusion occurred in more than 90% of SC/MASC cases (9,10,28). The fusion protein has transforming activity in multiple cell lineages and might have different effects in different organs, characteristics

Table 1 Genomic and immunohistochemical difference between SC/MASC and AciCC

Item	SC/MASC	AciCC
Genetic alteration		
<i>ETV6</i> split	+	-
Immunohistochemistry		
Mammaglobin	+	-
S100	++	+
Vimentin	++	+
DOG1	-	+

SC/MASC, secretory carcinoma/mammary analogue secretory carcinoma; AciCC, acinic cell carcinoma.

Table 2 Translocations and gene fusions in salivary gland cancers

Salivary gland cancers	Fusion genes	Translocations
SC/MASC	<i>ETV6-NTRK3</i>	t(12;15)(p13;q25)
AdCC	<i>MYB-NFIB</i>	t(6;9)(q22-23;p23-24)
HCCC	<i>EWSR1-ATF1</i>	t(12;22)(q13;q12)
	<i>CRTC1-MAML2</i>	t(11;19)(q21;p13)
MEC	<i>CRTC3-MAML2</i>	t(11;15)(q21;q26)
	<i>EWSR1-POU5F1</i>	t(6;22)(p21;q12)

SC/MASC, secretory carcinoma/mammary analogue secretory carcinoma; AdCC, adenoid cystic carcinoma; HCCC, hyalinizing clear cell carcinoma; MEC, mucoepidermoid carcinoma.

that are also described in infantile fibrosarcoma and acute myelogenous leukemias (22,30,31). *ETV6-NTRK3* translocation has been identified by fluorescence *in situ* hybridization (FISH), reverse transcription-polymerase chain reaction (RT-PCR), or both. For FISH analysis, a dual-color break-apart probe for the *ETV6* gene exhibits a split signal in the nuclei, which indicates that the *ETV6* gene is not intact (19). In analysis utilizing RT-PCR to identify the *ETV6* translocations, the 110-bp fusion transcript of the *ETV6-NTRK3* can be detected (19).

In AdCC, a fusion of the myeloblastosis oncogene (*MYB*) to the transcription factor nuclear factor I/B (*NFIB*) has been identified approximately in one-third or one-half of cases of this carcinoma. It has been demonstrated that *MYB* was overexpressed in the majority of AdCCs, not only in those with *MYB-NFIB* fusions but also in those without the fusion. This suggests that *MYB* may be crucial in the pathogenesis of AdCC (32).

HCCC is a rare, low-grade tumor with a good prognosis. A disease-defining translocation in the Ewing sarcoma RNA-binding protein 1 (*EWSR1*) gene was identified in more than 80% of HCCCs (33). A t(12;22)(q13;q12) translocation produces the most common fusion transcript consisting of the genes *EWSR1* and activating transcription factor 1 (*ATF1*) (28).

MEC harbors t(11;19)(q21;p13) translocation, which produces *CRTC1-MAML2* and less frequently *CRTC3-MAML2* t(11;15)(q21;q26) or *EWSR1-POU5F1* t(6;22)(p21;q12) (9,11,15,29,34). With regard to MEC, the fusion-positive cases tend to have better outcomes, less recurrence, fewer metastases, and lower tumor-related mortality than fusion-negative cases (35). Thus, those salivary tumors are not typically high grade or morphologically heterogeneous.

In addition to the above cancers, pleomorphic adenoma,

even though it is a benign mixed tumor, is known to have translocations involving *PLGA1* or *HMGA2* with a high probability (2,11,36).

Therapy for SC/MASC

SC/MASC often progresses slowly and is asymptomatic, and is generally regarded as a low-grade tumor. However, the clinical behavior of SC/MASC ranges from slowly growing tumors that infrequently recur after surgical resection to aggressive tumors that cause widespread metastasis and death. The initial choice of treatment is surgical resection, similarly to other salivary gland tumors. However, some patients with SC/MASC that is regarded as high-grade tumor received radiation therapy or chemoradiotherapy postoperatively (9,15). Although there was no statistically significant difference in the disease-free survival rate between SC/MASC and AcCC, some reports showed that the mean disease-free survival for patients with SC/MASC tended to be worse than that for patients with AcCC (8,9,15). Since the differences between SC/MASC and AcCC are slight in terms of clinicopathological features and outcome, the treatment for SC/MASC should follow those for AcCC. However, SC/MASC has a higher incidence of regional lymph node involvement and more aggressive behavior than AcCC (9,15). Most patients with SC/MASC appear to follow an indolent course, while certain cases appear predisposed to distant metastasis and increased mortality. *ETV6-NTRK3* translocation might have contributed to the clinicopathological difference between SC/MASC and AcCC, therefore, testing for *ETV6* translocation may be essential for the treatment of salivary gland tumors. In addition, *ETV6* translocation may have value in treatment and may represent a therapeutic target in SC/MASC. *ETV6* can fuse with other genes such as *ABL1*, *RUNX1* or *FLT3* (37-39). In leukemia, the fusion of the *ETV6* occasionally responds to TK inhibitors (37,38,40). Additionally, *in vitro* studies of mammary SC showed that insulin-like growth factor receptor 1 (IGFR1) inhibitors might be useful to block *ETV6-NTRK3* translocation-driven oncogenesis (6).

Conclusions

SC/MASC is a salivary gland tumor that is characterized by harboring *ETV6-NTRK3* translocation. In the near future, the identification of translocations and/or gene fusions will be a critical factor in diagnosing salivary gland tumors and

selecting appropriate treatments for them.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

- Ozguroglu M, Tascilar K, Ilvan S, et al. Secretory carcinoma of the breast. Case report and review of the literature. *Oncology* 2005;68:263-8.
- Thompson L. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. *Ear Nose Throat J* 2006; 85:74.
- Brandt SM, Swistel AJ, Rosen PP. Secretory carcinoma in the axilla: probable origin from axillary skin appendage glands in a young girl. *Am J Surg Pathol* 2009;33:950-3.
- Tognon C, Knezevich SR, Huntsman D, et al. Expression of the *ETV6-NTRK3* gene fusion as a primary event in human secretory breast carcinoma. *Cancer Cell* 2002;2:367-76.
- Laé M, Fréneaux P, Sastre-Garau X, et al. Secretory breast carcinomas with *ETV6-NTRK3* fusion gene belong to the basal-like carcinoma spectrum. *Mod Pathol* 2009;22:291-8.
- Tognon CE, Somasiri AM, Evdokimova VE, et al. *ETV6-NTRK3*-mediated breast epithelial cell transformation is blocked by targeting the *IGF1R* signaling pathway. *Cancer Res* 2011;71:1060-70.
- Wai DH, Knezevich SR, Lucas T, et al. The *ETV6-NTRK3* gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells. *Oncogene* 2000;19:906-15.
- Skálová A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the *ETV6-NTRK3* fusion gene: a hitherto undescribed salivary gland tumor entity. *Am J Surg Pathol* 2010;34:599-608.
- Chiosea SI, Griffith C, Assaad A, et al. Clinico-pathological characterization of mammary analogue secretory carcinoma of salivary glands. *Histopathology* 2012;61:387-94.
- Connor A, Perez-Ordoñez B, Shago M, et al. Mammary analog secretory carcinoma of salivary gland origin with the *ETV6* gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. *Am J Surg Pathol* 2012;36:27-34.
- Weinreb I. Translocation-associated salivary gland tumors: a review and update. *Adv Anat Pathol* 2013;20:367-77.
- Bishop JA, Yonescu R, Batista DA, et al. Cytopathologic features of mammary analogue secretory carcinoma. *Cancer Cytopathol* 2013; 121:228-33.
- Bishop JA, Yonescu R, Batista D, et al. Most nonparotid “acinic cell carcinomas” represent mammary analog secretory carcinomas. *Am J Surg Pathol* 2013;37:1053-7.
- Bishop JA. Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands. *Head Neck Pathol* 2013;7:35-9.
- Chiosea SI, Griffith C, Assaad A, et al. The profile of acinic cell carcinoma after recognition of mammary analog secretory carcinoma. *Am J Surg Pathol* 2012;36:343-50.
- Griffith CC, Stelow EB, Saqi A, et al. The cytological features of mammary analogue secretory carcinoma: a series of 6 molecularly confirmed cases. *Cancer Cytopathol* 2013;121:234-41.
- Levine P, Fried K, Krevitt LD, et al. Aspiration biopsy of mammary analogue secretory carcinoma of accessory parotid gland: another diagnostic dilemma in matrix-containing tumors of the salivary glands. *Diagn Cytopathol* 2014;42:49-53.
- Pisharodi L. Mammary analog secretory carcinoma of salivary gland: cytologic diagnosis and differential diagnosis of an unreported entity. *Diagn Cytopathol* 2013;41:239-41.
- Abe M, Inaki R, Kanno Y, et al. Molecular analysis of a mammary analog secretory carcinoma in the upper lip: Novel search for genetic and epigenetic abnormalities in MASC. *Int J Surg Case Rep* 2015;9:8-11.

20. Khalele BA. Systematic review of mammary analog secretory carcinoma of salivary glands at 7 years after description. *Head Neck* 2017;39:1243-8.
21. Pia-Foschini M, Reis-Filho JS, Eusebi V, et al. Salivary gland-like tumours of the breast: surgical and molecular pathology. *J Clin Pathol* 2003;56:497-506.
22. Knezevich SR, Garnett MJ, Pysher TJ, et al. *ETV6-NTRK3* gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. *Cancer Res* 1998;58:5046-48.
23. Said-Al-Naief N, Carlos R, Vance GH, et al. Combined DOG1 and mammaglobin immunohistochemistry is comparable to *ETV6*-breakapart analysis for differentiating between papillary cystic variants of acinic cell carcinoma and mammary analogue secretory carcinoma. *Int J Surg Pathol* 2017;25:127-40.
24. Khurram SA, Sultan-Khan J, Atkey N, et al. Cytogenetic and immunohistochemical characterization of mammary analogue secretory carcinoma of salivary glands. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2016;122:731-42.
25. Hsieh MS, Chou YH, Yeh SJ, et al. Papillary-cystic pattern is characteristic in mammary analogue secretory carcinomas but is rarely observed in acinic cell carcinomas of the salivary gland. *Virchows Arch* 2015;467:145-53.
26. Mariano FV, dos Santos HT, Azanero WD, et al. Mammary analogue secretory carcinoma of salivary glands is a lipid-rich tumour, and adipophilin can be valuable in its identification. *Histopathology* 2013;63:558-67.
27. Skalova A. Mammary analogue secretory carcinoma of salivary gland origin: an update and expanded morphologic and immunohistochemical spectrum of recently described entity. *Head Neck Pathol* 2013;7 Suppl 1:S30-6.
28. Stenman G. Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. *Head Neck Pathol* 2013;7 Suppl 1:S12-9.
29. Yin LX, Ha PK. Genetic alterations in salivary gland cancers. *Cancer* 2016;122:1822-31.
30. Bourgeois JM, Knezevich SR, Mathers JA, et al. Molecular detection of the *ETV6-NTRK3* gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. *Am J Surg Pathol* 2000;24:937-46.
31. Kralik JM, Kranewitter W, Boesmueller H, et al. Characterization of a newly identified *ETV6-NTRK3* fusion transcript in acute myeloid leukemia. *Diagn Pathol* 2011;6:19.
32. Mitani Y, Li J, Rao PH, et al. Comprehensive analysis of the *MYB-NFIB* gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. *Clin Cancer Res* 2010;16:4722-31.
33. Simpson RH, Skálová A, Di Palma S, et al. Recent advances in the diagnostic pathology of salivary carcinomas. *Virchows Arch* 2014;465:371-84.
34. Fehr A, Röser K, Heidorn K, et al. A new type of *MAML2* fusion in mucoepidermoid carcinoma. *Genes Chromosomes Cancer* 2008;47:203-6.
35. Behboudi A, Enlund F, Winnes M, et al. Molecular classification of mucoepidermoid carcinomas-prognostic significance of the *MECT1-MAML2* fusion oncogene. *Genes Chromosomes Cancer* 2006;45:470-81.
36. Abe M, Mori Y, Kanno Y, et al. A case of pleomorphic adenoma of the parotid gland with multiple local recurrences through facial to cervical region. *Open J Stomatol* 2014;4:441-5.
37. Walz C, Erben P, Ritter M, et al. Response of *ETV6-FLT3*-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. *Blood* 2011;118:2239-42.
38. Wlodarska I, Mecucci C, Baens M, et al. *ETV6* gene rearrangements in hematopoietic malignant disorders. *Leuk Lymphoma* 1996;23:287-95.
39. Jabber Al-Obaidi MS, Martineau M, Bennett CF, et al. *ETV6/AML1* fusion by FISH in adult acute lymphoblastic leukemia. *Leukemia* 2002;16:669-74.
40. O'Brien SG, Vieira SA, Connors S, et al. Transient response to imatinib mesylate (STI571) in a patient with the *ETV6-ABL* t(9;12) translocation. *Blood* 2002;99:3465-7.

Cite this article as: Inaki R, Abe M, Zong L, Abe T, Shinozaki-Ushiku A, Ushiku T, Hoshi K. Secretory carcinoma — impact of translocation and gene fusions on salivary gland tumor. *Chin J Cancer Res* 2017;29(5):379-384. doi: 10.21147/j.issn.1000-9604.2017.05.01